| Item Type | Name |
|
Concept
|
Pyrimidines
|
|
Academic Article
|
Isoform-selective phosphoinositide 3'-kinase inhibitors inhibit CXCR4 signaling and overcome stromal cell-mediated drug resistance in chronic lymphocytic leukemia: a novel therapeutic approach.
|
|
Academic Article
|
Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia.
|
|
Academic Article
|
Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial.
|
|
Academic Article
|
Three-year follow-up of treatment-na?ve and previously treated patients with CLL and SLL receiving single-agent ibrutinib.
|
|
Academic Article
|
Changes associated with the development of resistance to imatinib (STI571) in two leukemia cell lines expressing p210 Bcr/Abl protein.
|
|
Academic Article
|
Chronic myeloid leukemia and gastrointestinal stromal tumor: simultaneous presentation.
|
|
Academic Article
|
Significance of suboptimal response to imatinib, as defined by the European LeukemiaNet, in the long-term outcome of patients with early chronic myeloid leukemia in chronic phase.
|
|
Academic Article
|
Clinical impact of dose reductions and interruptions of second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukaemia.
|
|
Academic Article
|
Treatment of philadelphia chromosome-positive, accelerated-phase chronic myelogenous leukemia with imatinib mesylate.
|
|
Academic Article
|
Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy.
|
|
Academic Article
|
Efficacy of imatinib mesylate in the treatment of idiopathic hypereosinophilic syndrome.
|
|
Academic Article
|
Prediction of initial cytogenetic response for subsequent major and complete cytogenetic response to imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia.
|
|
Academic Article
|
Significance of myelofibrosis in early chronic-phase, chronic myelogenous leukemia on imatinib mesylate therapy.
|
|
Academic Article
|
A pilot study of imatinib, low-dose cytarabine and idarubicin for patients with chronic myeloid leukemia in myeloid blast phase.
|
|
Academic Article
|
The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo.
|
|
Academic Article
|
Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study.
|
|
Academic Article
|
Effects of age on prognosis with imatinib mesylate therapy for patients with Philadelphia chromosome-positive chronic myelogenous leukemia.
|
|
Academic Article
|
Survival advantage with imatinib mesylate therapy in chronic-phase chronic myelogenous ;eukemia (CML-CP) after IFN-alpha failure and in late CML-CP, comparison with historical controls.
|
|
Academic Article
|
Central nervous system relapse in two patients with chronic myelogenous leukemia in myeloid blastic phase on imatinib mesylate therapy.
|
|
Academic Article
|
Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy.
|
|
Academic Article
|
First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia.
|
|
Academic Article
|
Predictive factors for outcome and response in patients treated with second-generation tyrosine kinase inhibitors for chronic myeloid leukemia in chronic phase after imatinib failure.
|
|
Academic Article
|
Analysis of outcomes in adolescents and young adults with chronic myelogenous leukemia treated with upfront tyrosine kinase inhibitor therapy.
|
|
Academic Article
|
Selective, novel spleen tyrosine kinase (Syk) inhibitors suppress chronic lymphocytic leukemia B-cell activation and migration.
|
|
Academic Article
|
Kinetics of CLL cells in tissues and blood during therapy with the BTK inhibitor ibrutinib.
|
|
Academic Article
|
The significance of myelosuppression during therapy with imatinib mesylate in patients with chronic myelogenous leukemia in chronic phase.
|
|
Academic Article
|
Bleeding diathesis in patients with chronic myelogenous leukemia receiving dasatinib therapy.
|
|
Academic Article
|
Long-term outcome of patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR-ABL kinase domain mutations.
|
|
Academic Article
|
Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase: comparison with historic data.
|
|
Academic Article
|
Ibrutinib: a paradigm shift in management of CLL.
|
|
Academic Article
|
Trisomy 12 is associated with an abbreviated redistribution lymphocytosis during treatment with the BTK inhibitor ibrutinib in patients with chronic lymphocytic leukaemia.
|
|
Academic Article
|
Proteasome inhibitor carfilzomib complements ibrutinib's action in chronic lymphocytic leukemia.
|
|
Academic Article
|
Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib.
|
|
Academic Article
|
Three newly approved drugs for chronic lymphocytic leukemia: incorporating ibrutinib, idelalisib, and obinutuzumab into clinical practice.
|
|
Academic Article
|
Pharmacological and Protein Profiling Suggests Venetoclax (ABT-199) as Optimal Partner with Ibrutinib in Chronic Lymphocytic Leukemia.
|
|
Academic Article
|
Outcomes of Patients With Chronic Lymphocytic Leukemia and Richter's Transformation After Transplantation Failure.
|
|
Academic Article
|
The phosphoinositide-3-kinase (PI3K)-delta and gamma inhibitor, IPI-145 (Duvelisib), overcomes signals from the PI3K/AKT/S6 pathway and promotes apoptosis in CLL.
|
|
Academic Article
|
Complex karyotype is a stronger predictor than del(17p) for an inferior outcome in relapsed or refractory chronic lymphocytic leukemia patients treated with ibrutinib-based regimens.
|
|
Academic Article
|
CCL3 and CCL4 are biomarkers for B cell receptor pathway activation and prognostic serum markers in diffuse large B cell lymphoma.
|
|
Academic Article
|
Long-term molecular and cytogenetic response and survival outcomes with imatinib 400 mg, imatinib 800 mg, dasatinib, and nilotinib in patients with chronic-phase chronic myeloid leukaemia: retrospective analysis of patient data from five clinical trials.
|
|
Academic Article
|
Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition.
|
|
Academic Article
|
Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial.
|
|
Academic Article
|
Analysis of 2013 European LeukaemiaNet (ELN) responses in chronic phase CML across four frontline TKI modalities and impact on clinical outcomes.
|
|
Academic Article
|
Autoimmune cytopenias in patients with chronic lymphocytic leukemia treated with ibrutinib.
|
|
Academic Article
|
?2 -microglobulin normalization within 6 months of ibrutinib-based treatment is associated with superior progression-free survival in patients with chronic lymphocytic leukemia.
|
|
Academic Article
|
Preclinical combination of TP-0903, an AXL inhibitor and B-PAC-1, a procaspase-activating compound with ibrutinib in chronic lymphocytic leukemia.
|
|
Academic Article
|
Frontline therapy with high-dose imatinib versus second generation tyrosine kinase inhibitor in patients with chronic-phase chronic myeloid leukemia - a propensity score analysis.
|
|
Academic Article
|
Extended Treatment with Single-Agent Ibrutinib at the 420 mg Dose Leads to Durable Responses in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.
|
|
Academic Article
|
Ibrutinib Therapy Increases T Cell Repertoire Diversity in Patients with Chronic Lymphocytic Leukemia.
|
|
Academic Article
|
Leukemia cell proliferation and death in chronic lymphocytic leukemia patients on therapy with the BTK inhibitor ibrutinib.
|
|
Academic Article
|
Long-term Follow-up of Treatment with Ibrutinib and Rituximab in Patients with High-Risk Chronic Lymphocytic Leukemia.
|
|
Academic Article
|
Comparison of Acalabrutinib, A Selective Bruton Tyrosine Kinase Inhibitor, with Ibrutinib in Chronic Lymphocytic Leukemia Cells.
|
|
Academic Article
|
Long-term outcomes for patients with chronic lymphocytic leukemia who discontinue ibrutinib.
|
|
Academic Article
|
Ibrutinib modulates the immunosuppressive CLL microenvironment through STAT3-mediated suppression of regulatory B-cell function and inhibition of the PD-1/PD-L1 pathway.
|
|
Academic Article
|
Pharmacodynamics and proteomic analysis of acalabrutinib therapy: similarity of on-target effects to ibrutinib and rationale for combination therapy.
|
|
Academic Article
|
Ibrutinib inhibits free fatty acid metabolism in chronic lymphocytic leukemia.
|
|
Academic Article
|
Single-agent ibrutinib in treatment-na?ve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience.
|
|
Academic Article
|
A prospective analysis of symptom burden for patients with chronic myeloid leukemia in chronic phase treated with frontline second- and third-generation tyrosine kinase inhibitors.
|
|
Academic Article
|
Evaluation of 230 patients with relapsed/refractory deletion 17p chronic lymphocytic?leukaemia treated with ibrutinib from 3 clinical trials.
|
|
Academic Article
|
Tumour debulking and reduction in predicted risk of tumour lysis syndrome with single-agent ibrutinib in patients with chronic lymphocytic leukaemia.
|
|
Academic Article
|
Targeted multigene deep sequencing of Bruton tyrosine kinase inhibitor-resistant chronic lymphocytic leukemia with disease progression and Richter transformation.
|
|
Academic Article
|
Tolerability and activity of ublituximab, umbralisib, and ibrutinib in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: a phase 1 dose escalation and expansion trial.
|
|
Academic Article
|
Randomized trial of ibrutinib vs ibrutinib plus rituximab in patients with chronic lymphocytic leukemia.
|
|
Academic Article
|
A pilot study of lower doses of ibrutinib in patients with chronic lymphocytic leukemia.
|
|
Academic Article
|
Ibrutinib and Venetoclax for First-Line Treatment of CLL.
|
|
Academic Article
|
Does FCR have the potential to cure a subgroup of patients with chronic lymphocytic leukemia?
|
|
Academic Article
|
Ibrutinib and Venetoclax for First-Line Treatment of CLL. Reply.
|
|
Academic Article
|
Achieving complete remission in CLL patients treated with ibrutinib: clinical significance and predictive factors.
|
|
Academic Article
|
Incidental Richter transformation in chronic lymphocytic leukemia patients during temporary interruption of ibrutinib.
|
|
Academic Article
|
Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study.
|